DOJ Opposes Sanofi’s Move to Head Off 340B Dispute Resolution in Contract Pharmacy Battle

The U.S. Justice Department (DOJ) has slammed a second drug manufacturer’s motion before a federal court to block implementation of the 340B program’s new administrative dispute resolution (ADR) process.

First, on Feb. 16 in a federal district court in Indiana, DOJ forcefully opposed Eli Lilly’s motion for an injunction against the ADR process. Then, nine days later, in federal district court in New Jersey, DOJ likewise forcefully opposed Sanofi’s Feb. 2 motion challenging the 340B ADR rule.

The U.S. Justice Department (DOJ) has slammed a second drug manufacturer’s motion before a federal court to block implementation of the 340B program’s new administrative dispute resolution (ADR) process.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report